US 11,357,778 · Application 16/662,126 · Granted Jun 14, 2022
US 11,357,778
Antagonist of the fibroblast growth factor receptor 3 (fgfr3) for use in the treatment or the prevention of skeletal disorders linked with abnormal activation of fgfr3
Estimated expiration
December 12, 2032
6y 87d remaining
- Could not fetch continuity data for application PCTEP2012075294: Resource not found (404)
Earliest effective filing
Dec 12, 2012
+ 20 years
Dec 12, 2032
PTA +0d
Dec 12, 2032
TD cap (US 9,931,341)
Dec 12, 2032
Final
Dec 12, 2032
This calculation includes patent term adjustment (PTA) under 35 U.S.C. §154(b). Patent term extension (PTE) under 35 U.S.C. §156 (for FDA-regulated products) is not included. Terminal disclaimers can affect PTA (In re Cellect, LLC).
Calculation details
Base term
- Filing date
- October 24, 2019
- Earliest effective filing
- December 12, 2012
- Issue date
- June 14, 2022
- PTA
- 0 days
- Base expiry (before PTA)
- December 12, 2032
December 12, 2012 + 20 years = December 12, 2032
- Continuation of application 15/872,307, filed Jan 16, 2018
- Continuation of application 14/844,041, filed Sep 3, 2015, issued as US 9,931,341
- Continuation of application 14/364,320, filed Jun 11, 2014
- National stage entry of application PCTEP2012075294, filed Dec 12, 2012
- National stage entry of application PCTEP2012075294, filed Dec 12, 2012
- Continuation of application 14/364,320, filed Jun 11, 2014
- National stage entry of application PCTEP2012075294, filed Dec 12, 2012
- Continuation of application 14/844,041, filed Sep 3, 2015, issued as US 9,931,341
- Continuation of application 14/364,320, filed Jun 11, 2014
- National stage entry of application PCTEP2012075294, filed Dec 12, 2012
Terminal disclaimers
TD caps expiration to December 12, 2032 (earliest expiring referenced patent: US 9,931,341)
US 11,450,278· Application 17/466,154Capping patent
Display device and display device driving method
- Filing date
- Sep 3, 2021
- Earliest effective filing
- Sep 3, 2021
- Issue date
- Sep 20, 2022
- PTA
- 0 days
- Calculated expiration
- Sep 3, 2041
Sep 3, 2021 + 20y = Sep 3, 2041
US 9,931,341· Application 14/844,041Capping patent
Antagonist of the fibroblast growth factor receptor 3 (fgfr3) for use in the treatment or the prevention of skeletal disorders linked with abnormal activation of fgfr3
- Filing date
- Sep 3, 2015
- Earliest effective filing
- Dec 12, 2012
- Issue date
- Apr 3, 2018
- PTA
- 0 days
- Calculated expiration
- Dec 12, 2032
Continuation of 14/364,320, filed Jun 11, 2014
National stage entry of PCTEP2012075294, filed Dec 12, 2012
National stage entry of PCTEP2012075294, filed Dec 12, 2012
Dec 12, 2012 + 20y = Dec 12, 2032
US 11,357,778· Application 16/662,126(from application 16/662,126)
Antagonist of the fibroblast growth factor receptor 3 (fgfr3) for use in the treatment or the prevention of skeletal disorders linked with abnormal activation of fgfr3
- Filing date
- Oct 24, 2019
- Earliest effective filing
- Dec 12, 2012
- Issue date
- Jun 14, 2022
- PTA
- 0 days
- Calculated expiration
- Dec 12, 2032
Continuation of 15/872,307, filed Jan 16, 2018
Continuation of 14/844,041, filed Sep 3, 2015, issued as US 9,931,341
Continuation of 14/364,320, filed Jun 11, 2014
National stage entry of PCTEP2012075294, filed Dec 12, 2012
National stage entry of PCTEP2012075294, filed Dec 12, 2012
Continuation of 14/364,320, filed Jun 11, 2014
National stage entry of PCTEP2012075294, filed Dec 12, 2012
Continuation of 14/844,041, filed Sep 3, 2015, issued as US 9,931,341
Continuation of 14/364,320, filed Jun 11, 2014
National stage entry of PCTEP2012075294, filed Dec 12, 2012
Dec 12, 2012 + 20y = Dec 12, 2032
Patent term extension under 35 U.S.C. §156, which can apply to certain drug, biologic, animal drug and medical device patents, is not included in this calculation. How PTE is calculated
The prosecution record for your AI
Application 16/662,126 · US 11,357,778
You have the date. Your AI can have the file.
PatentReply compiles the prosecution history behind US 11,357,778: the claims as filed and as allowed, every Office Action and response, and the cited references, with each answer pointing back to the filed passage.
One public application a month is free. The first compile takes a few minutes.
Strategy and filing changes require your approval.
Permanent link
www.patentreply.ai/tools/patent-expiration/US11357778Data sourced from public USPTO records. This tool provides informational estimates and should not be relied upon as legal advice. Always verify patent expiration dates independently, especially where patent term extension, terminal disclaimers, or unusual continuity issues may apply.